SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending due to increased interest in quantum computing stocks, spurred by news of a substantial investment in quantum technologies. The community is actively discussing the potential for a short squeeze and comparing RGTI to other quantum and AI-related stocks. High trading volume and positive market sentiment are contributing to the stock's upward momentum.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending amid discussions of its strategic shift towards quantum computing for cryptocurrency applications, particularly its partnership with LightSolver and potential for energy-efficient blockchain solutions. The community is comparing QCLS to other quantum and crypto stocks, with traders closely monitoring its low float and threshold list status. Speculation around news and potential contracts is also fueling interest.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending due to a recent surge, with the community discussing its strong balance sheet, real-world applications, and potential for further gains. Bullish sentiment is fueled by news of institutional interest and successful deployments of their quantum solvers. Some are drawing comparisons to the dot-com bubble, while others see $QBTS as a long-term play in the burgeoning quantum computing sector.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

AAPL is trending due to a mixed analyst outlook, highlighted by Jefferies downgrading the stock to Underperform while Morgan Stanley raised its price target significantly, sparking debate among investors about the company's valuation and future performance. The community is actively discussing the credibility of these differing analyses and their potential impact on Apple's stock price, while also eyeing potential upside catalysts such as strong iPhone 17 sales and long-term bullish positioning by institutions.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending following the announcement of a partnership with AI search engine Perplexity, aimed at enhancing video discovery on the platform. The community is buzzing about the potential impact of this collaboration, especially regarding AI-driven content recommendations and a new subscription bundle. Some traders speculate about a possible short squeeze, referencing the high short interest and significant call option activity.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending due to a planned $500 million private placement, sparking discussions about dilution and the company's growth prospects. Community members are debating the stock's valuation relative to its revenue and comparing it to other quantum computing stocks like IONQ and RGTI. Some traders are optimistic about the future of quantum computing and government support, while others express skepticism and highlight potential risks.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors discuss positive momentum and a potential short squeeze, with community members pointing to the stock being undervalued. Renewed optimism surrounds upcoming data releases, revenue potential and speculation around a buyout, while some traders monitor options activity for bullish signals. Community members are actively discussing resistance levels and expressing optimism about the stock's long-term potential amid volatility.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to its position in the quantum computing sector, with community members actively discussing its high valuation and potential for future growth. News surrounding government funding and partnerships, including potential collaborations with NVIDIA, are also driving interest.  Additionally, some investors are closely watching for potential short squeezes and dilution.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors discuss the implications of an upcoming warrant distribution and a mixed securities shelf offering. The community is split, with some viewing the warrant as a positive catalyst for a potential squeeze, while others express concern about possible dilution and the actions of company leadership. The stock's volatile price action and potential for manipulation are also key discussion points.

GSR III Acquisition Corp engages in the merger, share exchange, asset acquisition, share purchase or reorganization with one or more businesses. The company was founded on May 10, 2023 and is headquartered in Austin, Texas.

GSR III Acquisition Corp. - Ordinary Shares- Class A

GSR III Acquisition Corp. Ordinary Shares

GSRT is trending due to its upcoming merger with Terra Innovatum, a nuclear energy company, generating community discussion about the potential of the micro-modular reactor technology and comparison to sector peers. Community members are weighing the risks and potential rewards associated with holding through the merger and ticker change, while also considering the broader context of renewed interest in nuclear energy. Some traders point to unusual options activity and analyst coverage as potential catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Harrow (HROW) announced on Friday that it has entered into an agreement to acquire privately held Melt Pharmaceuticals for an undisclosed price.While Harrow is a provider of ophthalmic disease management solutions, Melt Pharmaceuticals is focused on developing non-opioid therapies for sedation during medical procedures. Melt was spun out of Harrow in January 2019.The acquisition will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.harrow.com/news-releases/news-release-details/harrow-acquire-melt-pharmaceuticals">include</a> Melt’s lead investigational therapy, MELT-300, a sublingually delivered formulation of a fixed dose of Midazolam (3mg) and Ketamine (50mg) designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration.Shares of Harrow jumped 4% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HROW">HROW stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.MELT-300 was found to be statistically superior to both sublingual Midazolam alone and placebo in providing successful procedural sedation in a late-stage study. A recently completed cardiac safety study also indicated that MELT-300 did not alter normal heart rhythm, supporting the therapy’s safety profile. Harrow now plans to submit a new drug application to the U.S. Food and Drug Administration for the sedative in 2027, and is eyeing a commercial launch in the U.S. in 2028.If the FDA approves MELT-300, the company intends to discontinue the MKO Melt sedation product, marketed through its ImprimisRx subsidiary, for cataract surgeries. The company also sees potential for MELT-300 to be used in other procedures, including claustrophobia during MRIs, sedation for colonoscopies, dental procedures, gastroenterology procedures, and other interventions.The closing of the merger transaction, however, is subject to customary closing conditions, including approval by Melt shareholders, Harrow added.HROW stock is up 43% this year and by about 9% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/costco-draws-mixed-reactions-from-wall-street-despite-q4-beat-here-is-why/chDVjZGR3eX">Costco Draws Mixed Reactions From Wall Street Despite Q4 Beat: Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration. 

Equity

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration. 


Surging Earnings Estimates Signal Upside for Harrow (HROW) Stock

Harrow (HROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Best Momentum Stock to Buy for August 15th

ECG, NVT and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 15, 2025.

Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a Bet

The mean of analysts' price targets for Harrow (HROW) points to a 53.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar?

Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Are Options Traders Betting on a Big Move in Harrow Stock?

Investors need to pay close attention to HROW stock based on the movements in the options market lately.

Harrow Health, Inc reported a wider first-quarter loss on Thursday but reaffirmed its full-year revenue outlook, prompting a pickup in retail trading activity.The eyecare pharmaceutical firm posted a net loss of $17.8 million, or 38 cents per share, compared with a loss of $13.6 million, or 28 cents per share, a year earlier.&nbsp;Harrow shares closed at $23.59, down 4.07% on Thursday, and dropped further in after-hours trading, falling $2.49, or 10.56% to $21.10.Revenue rose 38% year-over-year to $47.8 million, driven by increased uptake of Vevye, a prescription ophthalmic drug for dry eye disease.&nbsp;Vevye recorded $21.5 million in sales during the quarter.The company cited strong early demand from its new ‘Vevye Access for All’ program, launched in mid-March, with prescription volumes at specialty pharmacy PhilRx more than quadrupling.“Our Vevye refill rate continues to be buoyant, with the average covered patient receiving nine refills,” CEO Mark L. Baum said in a statement.Harrow reaffirmed its 2025 revenue target of over $280 million, slightly below analysts’ average estimate of $283.2 million.&nbsp;The company said it expects continued commercial momentum from its Iheezo and Triesence products, along with contributions from pending pipeline accounts.Management also reiterated its focus on strategic acquisitions to augment its U.S. commercial platform, calling out opportunities to add “high-quality ophthalmic pharmaceutical assets.”Sentiment on Stocktwits was described as "extremely bullish," amid a 2,200% surge in 24-hour message volume.One user expressed strong enthusiasm for the stock, commenting that there was "never a bad price to buy HROW" and that no matter the outcome, it's always "good news."&nbsp;<stembedurl>https://stocktwits.com/dpen1000/message/614022779</stembedurl>Another user highlighted the potential for VEVYE’s continued growth, noting that if it maintains its 35% quarter-over-quarter increase, the product alone could contribute $150 million in revenue for 2025.<stembedurl>https://stocktwits.com/HROW200/message/614007884</stembedurl>The stock has declined over 35% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Harrow Health Posts Larger Loss In Q1, But Retail Enthusiasm Grows As Dry Eye Disease Drug Drives Revenue

The company reported a net loss of $17.8 million, or 38 cents per share, compared to a loss of $13.6 million in the same period last year. Despite the wider loss, Harrow reiterated its 2025 revenue target of over $280 million.

Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates

Stock Index Futures Gain With All Eyes on Fed Rate Decision

March S&P 500 E-Mini futures (ESH25) are up +0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.22% this morning, pointing to a slightly higher open on Wall Street as investors await the Federal Reserve’s policy decision and Chair Jerome Powell’s comments.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

HROW
Harrow Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest HROW News

HROW Harrow Health Inc